| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Peripheral Arterial Disease | 71 | 2023 | 377 | 26.590 |
Why?
|
| Myocardial Infarction | 80 | 2023 | 968 | 15.050 |
Why?
|
| Platelet Aggregation Inhibitors | 64 | 2023 | 402 | 13.590 |
Why?
|
| Lactones | 24 | 2022 | 57 | 6.930 |
Why?
|
| Acute Coronary Syndrome | 33 | 2024 | 257 | 6.920 |
Why?
|
| Stroke | 38 | 2023 | 1047 | 6.820 |
Why?
|
| Rivaroxaban | 19 | 2023 | 208 | 6.520 |
Why?
|
| Pyridines | 27 | 2022 | 440 | 6.170 |
Why?
|
| Thrombosis | 18 | 2023 | 309 | 5.940 |
Why?
|
| Adenosine | 19 | 2023 | 211 | 5.920 |
Why?
|
| Secondary Prevention | 40 | 2023 | 227 | 5.880 |
Why?
|
| Aspirin | 26 | 2023 | 334 | 5.710 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 24 | 2023 | 62 | 5.410 |
Why?
|
| Atherosclerosis | 20 | 2023 | 345 | 5.330 |
Why?
|
| Vascular Surgical Procedures | 11 | 2023 | 262 | 4.500 |
Why?
|
| Ischemia | 21 | 2023 | 374 | 4.480 |
Why?
|
| Endovascular Procedures | 11 | 2023 | 276 | 4.260 |
Why?
|
| Lower Extremity | 18 | 2023 | 335 | 4.030 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 13 | 2024 | 387 | 3.850 |
Why?
|
| Fibrinolytic Agents | 12 | 2022 | 238 | 3.810 |
Why?
|
| Hemorrhage | 34 | 2023 | 623 | 3.570 |
Why?
|
| Factor Xa Inhibitors | 12 | 2022 | 138 | 3.440 |
Why?
|
| Cardiovascular Diseases | 26 | 2023 | 1797 | 3.290 |
Why?
|
| Troponin I | 10 | 2022 | 83 | 3.280 |
Why?
|
| Treatment Outcome | 80 | 2023 | 9341 | 3.220 |
Why?
|
| Anticholesteremic Agents | 7 | 2024 | 130 | 3.030 |
Why?
|
| Venous Thromboembolism | 11 | 2023 | 234 | 3.030 |
Why?
|
| Diabetes Mellitus, Type 2 | 22 | 2023 | 2174 | 2.820 |
Why?
|
| Brain Ischemia | 8 | 2022 | 310 | 2.780 |
Why?
|
| Thrombolytic Therapy | 8 | 2021 | 118 | 2.600 |
Why?
|
| Humans | 228 | 2024 | 118959 | 2.590 |
Why?
|
| Aged | 110 | 2023 | 19652 | 2.530 |
Why?
|
| Risk Factors | 63 | 2023 | 8999 | 2.470 |
Why?
|
| Drug-Eluting Stents | 4 | 2023 | 66 | 2.310 |
Why?
|
| Diabetes Mellitus | 11 | 2023 | 942 | 2.170 |
Why?
|
| Drug Therapy, Combination | 22 | 2023 | 965 | 2.130 |
Why?
|
| Aortic Diseases | 4 | 2021 | 94 | 2.100 |
Why?
|
| Dyslipidemias | 4 | 2021 | 162 | 2.090 |
Why?
|
| Middle Aged | 98 | 2023 | 27613 | 2.050 |
Why?
|
| Renal Insufficiency, Chronic | 5 | 2022 | 589 | 2.020 |
Why?
|
| Coronary Artery Disease | 10 | 2021 | 647 | 1.980 |
Why?
|
| Risk Assessment | 28 | 2021 | 3055 | 1.950 |
Why?
|
| Receptor, PAR-1 | 10 | 2019 | 21 | 1.940 |
Why?
|
| Double-Blind Method | 39 | 2021 | 1687 | 1.870 |
Why?
|
| Glucosides | 8 | 2020 | 39 | 1.790 |
Why?
|
| Male | 121 | 2023 | 57795 | 1.790 |
Why?
|
| Benzhydryl Compounds | 8 | 2020 | 60 | 1.750 |
Why?
|
| Heart Failure | 15 | 2023 | 1969 | 1.710 |
Why?
|
| Female | 119 | 2023 | 61559 | 1.700 |
Why?
|
| Anticoagulants | 12 | 2023 | 559 | 1.670 |
Why?
|
| ST Elevation Myocardial Infarction | 5 | 2022 | 51 | 1.470 |
Why?
|
| Blood Coagulation Disorders | 2 | 2023 | 208 | 1.450 |
Why?
|
| Embolism | 2 | 2022 | 43 | 1.430 |
Why?
|
| Troponin T | 6 | 2022 | 50 | 1.390 |
Why?
|
| Hypolipidemic Agents | 2 | 2021 | 86 | 1.380 |
Why?
|
| Extremities | 6 | 2021 | 113 | 1.320 |
Why?
|
| Coronary Thrombosis | 4 | 2018 | 25 | 1.310 |
Why?
|
| Follow-Up Studies | 27 | 2022 | 4596 | 1.300 |
Why?
|
| Cholesterol, LDL | 6 | 2024 | 316 | 1.250 |
Why?
|
| Piperazines | 8 | 2014 | 316 | 1.170 |
Why?
|
| Receptors, Thrombin | 5 | 2015 | 12 | 1.170 |
Why?
|
| Time Factors | 30 | 2022 | 6411 | 1.160 |
Why?
|
| Phosphatidylcholine-Sterol O-Acyltransferase | 2 | 2022 | 5 | 1.110 |
Why?
|
| Sterol O-Acyltransferase | 2 | 2022 | 4 | 1.090 |
Why?
|
| Cardiovascular Agents | 4 | 2022 | 126 | 1.090 |
Why?
|
| Electrocardiography | 8 | 2018 | 556 | 1.090 |
Why?
|
| Biomarkers | 28 | 2023 | 3588 | 1.080 |
Why?
|
| Randomized Controlled Trials as Topic | 17 | 2023 | 1244 | 1.060 |
Why?
|
| Hypercholesterolemia | 2 | 2024 | 93 | 1.060 |
Why?
|
| Percutaneous Coronary Intervention | 5 | 2021 | 455 | 1.050 |
Why?
|
| Walking | 5 | 2022 | 414 | 1.040 |
Why?
|
| Kaplan-Meier Estimate | 15 | 2022 | 841 | 1.040 |
Why?
|
| Myocardial Ischemia | 6 | 2021 | 251 | 1.030 |
Why?
|
| Atrial Fibrillation | 3 | 2023 | 338 | 0.950 |
Why?
|
| Kidney Diseases | 5 | 2020 | 439 | 0.950 |
Why?
|
| Chest Pain | 4 | 2017 | 84 | 0.950 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 2 | 2023 | 79 | 0.940 |
Why?
|
| Prasugrel Hydrochloride | 5 | 2020 | 18 | 0.940 |
Why?
|
| Cardiology | 3 | 2022 | 272 | 0.930 |
Why?
|
| Acute Disease | 8 | 2021 | 940 | 0.930 |
Why?
|
| Ventricular Function, Left | 3 | 2023 | 468 | 0.920 |
Why?
|
| Incidence | 14 | 2023 | 2424 | 0.910 |
Why?
|
| Acetanilides | 6 | 2014 | 11 | 0.910 |
Why?
|
| Vascular Diseases | 3 | 2023 | 241 | 0.890 |
Why?
|
| Anterior Wall Myocardial Infarction | 1 | 2022 | 2 | 0.890 |
Why?
|
| Antifibrinolytic Agents | 1 | 2023 | 44 | 0.890 |
Why?
|
| Hospitalization | 8 | 2023 | 1785 | 0.840 |
Why?
|
| Paclitaxel | 2 | 2021 | 195 | 0.810 |
Why?
|
| Serine Proteinase Inhibitors | 2 | 2020 | 35 | 0.810 |
Why?
|
| Dyspnea | 2 | 2020 | 200 | 0.800 |
Why?
|
| Proprotein Convertase 9 | 6 | 2021 | 60 | 0.780 |
Why?
|
| Cerebrovascular Disorders | 2 | 2018 | 86 | 0.780 |
Why?
|
| Beneficence | 1 | 2021 | 18 | 0.780 |
Why?
|
| Myocarditis | 2 | 2019 | 95 | 0.770 |
Why?
|
| Platelet Aggregation | 5 | 2023 | 97 | 0.770 |
Why?
|
| Recurrence | 18 | 2022 | 975 | 0.760 |
Why?
|
| Research Subjects | 1 | 2021 | 40 | 0.760 |
Why?
|
| Personal Autonomy | 1 | 2021 | 41 | 0.760 |
Why?
|
| Prospective Studies | 20 | 2022 | 6471 | 0.760 |
Why?
|
| Postoperative Complications | 2 | 2021 | 2235 | 0.760 |
Why?
|
| Sex Characteristics | 2 | 2023 | 671 | 0.740 |
Why?
|
| Limb Salvage | 5 | 2023 | 52 | 0.740 |
Why?
|
| Cholesterol | 4 | 2022 | 373 | 0.740 |
Why?
|
| Renal Insufficiency | 2 | 2021 | 150 | 0.730 |
Why?
|
| Diabetes Complications | 2 | 2021 | 218 | 0.730 |
Why?
|
| Databases, Factual | 3 | 2021 | 1231 | 0.720 |
Why?
|
| Prognosis | 14 | 2023 | 3440 | 0.720 |
Why?
|
| Beverages | 1 | 2020 | 70 | 0.720 |
Why?
|
| Caffeine | 1 | 2020 | 61 | 0.720 |
Why?
|
| Informed Consent | 1 | 2021 | 163 | 0.720 |
Why?
|
| Patient Selection | 2 | 2021 | 676 | 0.710 |
Why?
|
| Leg | 1 | 2021 | 234 | 0.700 |
Why?
|
| Consensus | 2 | 2022 | 534 | 0.690 |
Why?
|
| Stents | 4 | 2021 | 457 | 0.680 |
Why?
|
| Ezetimibe | 1 | 2018 | 23 | 0.670 |
Why?
|
| Outpatients | 2 | 2023 | 325 | 0.670 |
Why?
|
| Aortic Aneurysm, Thoracic | 1 | 2020 | 121 | 0.670 |
Why?
|
| Syndrome | 5 | 2023 | 344 | 0.670 |
Why?
|
| Ovarian Neoplasms | 1 | 2023 | 420 | 0.660 |
Why?
|
| Natriuretic Peptide, Brain | 5 | 2023 | 106 | 0.640 |
Why?
|
| Blood Platelets | 5 | 2023 | 369 | 0.640 |
Why?
|
| Neoplasms | 3 | 2023 | 2178 | 0.630 |
Why?
|
| Diagnostic Imaging | 1 | 2020 | 294 | 0.630 |
Why?
|
| Dose-Response Relationship, Drug | 10 | 2021 | 1945 | 0.610 |
Why?
|
| Growth Differentiation Factor 15 | 3 | 2023 | 35 | 0.610 |
Why?
|
| Medical Oncology | 1 | 2019 | 229 | 0.600 |
Why?
|
| Proportional Hazards Models | 11 | 2021 | 1125 | 0.600 |
Why?
|
| Survival Rate | 6 | 2021 | 1720 | 0.600 |
Why?
|
| Disease Management | 1 | 2021 | 571 | 0.600 |
Why?
|
| Heparin | 3 | 2023 | 230 | 0.580 |
Why?
|
| Intermittent Claudication | 4 | 2022 | 109 | 0.580 |
Why?
|
| United States | 18 | 2023 | 12555 | 0.560 |
Why?
|
| Death, Sudden, Cardiac | 3 | 2018 | 166 | 0.540 |
Why?
|
| Patient Readmission | 1 | 2021 | 634 | 0.540 |
Why?
|
| Hypoglycemic Agents | 9 | 2022 | 1032 | 0.540 |
Why?
|
| Cause of Death | 7 | 2021 | 380 | 0.530 |
Why?
|
| Enzyme Inhibitors | 5 | 2014 | 827 | 0.530 |
Why?
|
| Ulcer | 2 | 2021 | 28 | 0.530 |
Why?
|
| Hematoma | 2 | 2021 | 51 | 0.520 |
Why?
|
| Drug Administration Schedule | 8 | 2022 | 736 | 0.520 |
Why?
|
| Non-ST Elevated Myocardial Infarction | 3 | 2019 | 16 | 0.510 |
Why?
|
| Benzazepines | 3 | 2019 | 38 | 0.500 |
Why?
|
| Antibodies, Monoclonal | 2 | 2018 | 1284 | 0.490 |
Why?
|
| Medicare | 7 | 2023 | 663 | 0.480 |
Why?
|
| Hypertension | 2 | 2022 | 1203 | 0.480 |
Why?
|
| Thiophenes | 2 | 2011 | 106 | 0.480 |
Why?
|
| Global Health | 4 | 2021 | 310 | 0.480 |
Why?
|
| Diabetic Cardiomyopathies | 3 | 2019 | 39 | 0.470 |
Why?
|
| Quality of Life | 2 | 2022 | 2363 | 0.460 |
Why?
|
| Ranolazine | 7 | 2014 | 21 | 0.450 |
Why?
|
| Life Style | 1 | 2015 | 430 | 0.440 |
Why?
|
| Lecithins | 2 | 2022 | 4 | 0.440 |
Why?
|
| Pregnancy-Associated Plasma Protein-A | 1 | 2012 | 14 | 0.440 |
Why?
|
| Intracranial Hemorrhages | 5 | 2018 | 77 | 0.430 |
Why?
|
| Lipoproteins, HDL | 2 | 2022 | 82 | 0.420 |
Why?
|
| Stroke Volume | 4 | 2023 | 512 | 0.420 |
Why?
|
| MicroRNAs | 3 | 2023 | 637 | 0.420 |
Why?
|
| Cohort Studies | 10 | 2022 | 5116 | 0.420 |
Why?
|
| Multicenter Studies as Topic | 5 | 2021 | 253 | 0.420 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2021 | 2436 | 0.420 |
Why?
|
| Antibodies, Monoclonal, Humanized | 4 | 2021 | 667 | 0.400 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2012 | 140 | 0.400 |
Why?
|
| Diabetes Mellitus, Experimental | 2 | 2023 | 211 | 0.400 |
Why?
|
| Smoking Cessation | 1 | 2015 | 360 | 0.400 |
Why?
|
| Enoxaparin | 2 | 2021 | 51 | 0.390 |
Why?
|
| Thrombin | 3 | 2021 | 143 | 0.380 |
Why?
|
| Angina Pectoris | 2 | 2009 | 63 | 0.370 |
Why?
|
| Aged, 80 and over | 11 | 2022 | 6560 | 0.370 |
Why?
|
| Angioplasty, Balloon, Coronary | 2 | 2009 | 148 | 0.360 |
Why?
|
| Clinical Trials, Phase III as Topic | 5 | 2021 | 78 | 0.360 |
Why?
|
| Exercise | 2 | 2021 | 1655 | 0.350 |
Why?
|
| Appetite Depressants | 2 | 2019 | 21 | 0.340 |
Why?
|
| Coronary Artery Bypass | 3 | 2016 | 209 | 0.330 |
Why?
|
| Clinical Trials as Topic | 4 | 2021 | 969 | 0.330 |
Why?
|
| Troponin | 3 | 2020 | 47 | 0.320 |
Why?
|
| Hospital Mortality | 3 | 2021 | 814 | 0.320 |
Why?
|
| Europe | 3 | 2021 | 356 | 0.310 |
Why?
|
| Adult | 19 | 2023 | 31510 | 0.310 |
Why?
|
| Risk | 5 | 2019 | 853 | 0.310 |
Why?
|
| American Heart Association | 3 | 2022 | 270 | 0.310 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 2 | 2018 | 44 | 0.310 |
Why?
|
| Ticlopidine | 5 | 2016 | 61 | 0.310 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2019 | 156 | 0.290 |
Why?
|
| Combined Modality Therapy | 4 | 2020 | 1166 | 0.290 |
Why?
|
| Ventricular Function | 1 | 2006 | 60 | 0.290 |
Why?
|
| Glomerular Filtration Rate | 3 | 2019 | 683 | 0.290 |
Why?
|
| Metabolic Syndrome | 2 | 2021 | 394 | 0.290 |
Why?
|
| Popliteal Artery | 2 | 2023 | 59 | 0.280 |
Why?
|
| Internationality | 3 | 2022 | 152 | 0.280 |
Why?
|
| Thromboembolism | 2 | 2021 | 99 | 0.270 |
Why?
|
| Heparin, Low-Molecular-Weight | 2 | 2023 | 30 | 0.270 |
Why?
|
| Diabetic Nephropathies | 2 | 2019 | 289 | 0.260 |
Why?
|
| Angioplasty, Balloon | 3 | 2023 | 88 | 0.260 |
Why?
|
| Obesity | 4 | 2019 | 2746 | 0.260 |
Why?
|
| Ankle Brachial Index | 4 | 2022 | 30 | 0.260 |
Why?
|
| Peptide Fragments | 2 | 2023 | 702 | 0.260 |
Why?
|
| Immunotherapy | 2 | 2019 | 493 | 0.250 |
Why?
|
| Pravastatin | 2 | 2016 | 29 | 0.250 |
Why?
|
| Aortic Aneurysm | 2 | 2016 | 51 | 0.250 |
Why?
|
| Severity of Illness Index | 3 | 2018 | 2674 | 0.240 |
Why?
|
| Pragmatic Clinical Trials as Topic | 2 | 2021 | 49 | 0.240 |
Why?
|
| Comorbidity | 3 | 2020 | 1527 | 0.240 |
Why?
|
| Cardiovascular System | 2 | 2022 | 127 | 0.240 |
Why?
|
| Heptanoic Acids | 2 | 2015 | 62 | 0.240 |
Why?
|
| Registries | 5 | 2019 | 1810 | 0.230 |
Why?
|
| Angioplasty | 1 | 2023 | 39 | 0.230 |
Why?
|
| Psychiatric Rehabilitation | 1 | 2023 | 2 | 0.230 |
Why?
|
| Angina, Unstable | 3 | 2013 | 74 | 0.230 |
Why?
|
| Arteries | 2 | 2022 | 250 | 0.230 |
Why?
|
| Thromboplastin | 1 | 2023 | 68 | 0.230 |
Why?
|
| Retrospective Studies | 6 | 2023 | 12974 | 0.220 |
Why?
|
| Pyrroles | 2 | 2015 | 191 | 0.220 |
Why?
|
| Sensitivity and Specificity | 4 | 2014 | 1795 | 0.210 |
Why?
|
| Liraglutide | 1 | 2022 | 27 | 0.210 |
Why?
|
| Doxorubicin | 1 | 2023 | 302 | 0.210 |
Why?
|
| Predictive Value of Tests | 5 | 2018 | 1867 | 0.210 |
Why?
|
| Glucagon-Like Peptides | 1 | 2022 | 22 | 0.210 |
Why?
|
| Thiazoles | 1 | 2022 | 121 | 0.210 |
Why?
|
| Symporters | 1 | 2022 | 53 | 0.210 |
Why?
|
| Kidney | 2 | 2020 | 1353 | 0.210 |
Why?
|
| Numbers Needed To Treat | 1 | 2021 | 8 | 0.210 |
Why?
|
| Inflammation | 3 | 2023 | 2566 | 0.210 |
Why?
|
| Mobility Limitation | 1 | 2022 | 62 | 0.210 |
Why?
|
| Warfarin | 1 | 2022 | 139 | 0.200 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2023 | 181 | 0.200 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2021 | 15 | 0.200 |
Why?
|
| Myocardial Revascularization | 4 | 2021 | 72 | 0.200 |
Why?
|
| Exercise Therapy | 3 | 2022 | 355 | 0.190 |
Why?
|
| Placebos | 1 | 2021 | 202 | 0.190 |
Why?
|
| Drug Therapy | 1 | 2021 | 76 | 0.190 |
Why?
|
| Heart Diseases | 2 | 2016 | 340 | 0.190 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2021 | 180 | 0.190 |
Why?
|
| Blood Coagulation | 1 | 2021 | 219 | 0.180 |
Why?
|
| Methylamines | 1 | 2020 | 32 | 0.180 |
Why?
|
| Mobile Applications | 1 | 2022 | 147 | 0.180 |
Why?
|
| Lipoprotein(a) | 1 | 2020 | 49 | 0.180 |
Why?
|
| Reproducibility of Results | 4 | 2023 | 2874 | 0.180 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2022 | 174 | 0.180 |
Why?
|
| Survival Analysis | 2 | 2014 | 1266 | 0.180 |
Why?
|
| Weight Loss | 3 | 2019 | 655 | 0.180 |
Why?
|
| Glucagon-Like Peptide Receptors | 1 | 2019 | 1 | 0.180 |
Why?
|
| Biphenyl Compounds | 1 | 2019 | 52 | 0.180 |
Why?
|
| Osteoporosis, Postmenopausal | 1 | 2019 | 38 | 0.180 |
Why?
|
| Pharmaceutical Preparations | 1 | 2021 | 167 | 0.170 |
Why?
|
| Serotonin 5-HT2 Receptor Agonists | 1 | 2019 | 6 | 0.170 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2020 | 80 | 0.170 |
Why?
|
| Bone Density Conservation Agents | 1 | 2019 | 61 | 0.170 |
Why?
|
| Heart | 1 | 2023 | 631 | 0.170 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 2 | 2009 | 22 | 0.170 |
Why?
|
| Pharmacovigilance | 1 | 2018 | 13 | 0.170 |
Why?
|
| Hemoglobins | 1 | 2021 | 326 | 0.170 |
Why?
|
| Appetite Regulation | 1 | 2019 | 26 | 0.170 |
Why?
|
| Cardiac Rehabilitation | 1 | 2019 | 33 | 0.170 |
Why?
|
| Drug Approval | 2 | 2019 | 77 | 0.170 |
Why?
|
| Platelet Activation | 2 | 2017 | 70 | 0.170 |
Why?
|
| Adamantane | 1 | 2018 | 16 | 0.170 |
Why?
|
| Coronary Disease | 2 | 2018 | 356 | 0.170 |
Why?
|
| Microcirculation | 1 | 2019 | 155 | 0.170 |
Why?
|
| Reoperation | 1 | 2021 | 557 | 0.170 |
Why?
|
| Dipeptides | 1 | 2018 | 51 | 0.170 |
Why?
|
| Polyethylene Glycols | 1 | 2023 | 578 | 0.160 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2018 | 69 | 0.160 |
Why?
|
| Canagliflozin | 1 | 2018 | 11 | 0.160 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2023 | 1390 | 0.160 |
Why?
|
| Venous Thrombosis | 1 | 2020 | 147 | 0.160 |
Why?
|
| Anti-Obesity Agents | 1 | 2018 | 49 | 0.160 |
Why?
|
| Healthcare Disparities | 1 | 2023 | 496 | 0.160 |
Why?
|
| Research Personnel | 1 | 2020 | 158 | 0.160 |
Why?
|
| Inpatients | 1 | 2021 | 388 | 0.160 |
Why?
|
| Ischemic Attack, Transient | 2 | 2015 | 62 | 0.160 |
Why?
|
| Age Factors | 3 | 2022 | 2995 | 0.160 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2018 | 98 | 0.160 |
Why?
|
| Calibration | 1 | 2018 | 135 | 0.160 |
Why?
|
| Kidney Neoplasms | 1 | 2022 | 334 | 0.160 |
Why?
|
| Hyperglycemia | 1 | 2021 | 312 | 0.150 |
Why?
|
| Overweight | 2 | 2018 | 502 | 0.150 |
Why?
|
| Clinical Chemistry Tests | 2 | 2015 | 10 | 0.150 |
Why?
|
| Health Care Costs | 1 | 2021 | 394 | 0.150 |
Why?
|
| Young Adult | 5 | 2022 | 10793 | 0.150 |
Why?
|
| Uracil | 1 | 2017 | 35 | 0.150 |
Why?
|
| Pandemics | 2 | 2022 | 1355 | 0.150 |
Why?
|
| Morbidity | 1 | 2018 | 296 | 0.150 |
Why?
|
| Intestines | 1 | 2020 | 332 | 0.150 |
Why?
|
| Glycopeptides | 2 | 2014 | 58 | 0.150 |
Why?
|
| Vascular Patency | 1 | 2016 | 98 | 0.140 |
Why?
|
| Pericarditis | 1 | 2016 | 9 | 0.140 |
Why?
|
| Biological Assay | 2 | 2015 | 122 | 0.140 |
Why?
|
| Aortitis | 1 | 2016 | 7 | 0.140 |
Why?
|
| Vascular Grafting | 1 | 2016 | 12 | 0.140 |
Why?
|
| Uncertainty | 1 | 2016 | 101 | 0.140 |
Why?
|
| Marketing | 1 | 2016 | 25 | 0.140 |
Why?
|
| Smoking | 2 | 2021 | 1487 | 0.140 |
Why?
|
| Cyclopropanes | 1 | 2016 | 80 | 0.140 |
Why?
|
| Guideline Adherence | 1 | 2020 | 523 | 0.140 |
Why?
|
| Diabetic Angiopathies | 1 | 2018 | 260 | 0.140 |
Why?
|
| Multimodal Imaging | 1 | 2016 | 100 | 0.130 |
Why?
|
| Piperidines | 1 | 2017 | 171 | 0.130 |
Why?
|
| Algorithms | 2 | 2020 | 1541 | 0.130 |
Why?
|
| Exercise Tolerance | 1 | 2017 | 233 | 0.130 |
Why?
|
| Adiponectin | 1 | 2017 | 226 | 0.130 |
Why?
|
| ROC Curve | 2 | 2014 | 473 | 0.130 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2016 | 285 | 0.130 |
Why?
|
| France | 3 | 2019 | 35 | 0.130 |
Why?
|
| Down-Regulation | 1 | 2017 | 627 | 0.130 |
Why?
|
| Benzaldehydes | 1 | 2014 | 8 | 0.130 |
Why?
|
| Decision Support Techniques | 1 | 2018 | 364 | 0.130 |
Why?
|
| Oximes | 1 | 2014 | 18 | 0.130 |
Why?
|
| Simvastatin | 1 | 2015 | 65 | 0.130 |
Why?
|
| Mental Disorders | 1 | 2023 | 939 | 0.130 |
Why?
|
| International Cooperation | 2 | 2013 | 177 | 0.120 |
Why?
|
| Sleep | 1 | 2020 | 660 | 0.120 |
Why?
|
| Veterans | 2 | 2022 | 1207 | 0.120 |
Why?
|
| Emergency Service, Hospital | 3 | 2017 | 1864 | 0.120 |
Why?
|
| Genome-Wide Association Study | 1 | 2020 | 1323 | 0.120 |
Why?
|
| Hypoglycemia | 1 | 2018 | 400 | 0.120 |
Why?
|
| Biomedical Research | 1 | 2020 | 612 | 0.120 |
Why?
|
| Bacteria | 1 | 2020 | 757 | 0.120 |
Why?
|
| Periodicals as Topic | 1 | 2016 | 191 | 0.120 |
Why?
|
| Fatty Acid-Binding Proteins | 1 | 2013 | 62 | 0.120 |
Why?
|
| Social Media | 1 | 2016 | 133 | 0.120 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2020 | 548 | 0.110 |
Why?
|
| C-Reactive Protein | 2 | 2016 | 360 | 0.110 |
Why?
|
| Calgranulin A | 1 | 2012 | 5 | 0.110 |
Why?
|
| Calgranulin B | 1 | 2012 | 6 | 0.110 |
Why?
|
| Blood Proteins | 1 | 2014 | 248 | 0.110 |
Why?
|
| Pregnancy Proteins | 1 | 2012 | 38 | 0.110 |
Why?
|
| Osteoprotegerin | 1 | 2012 | 23 | 0.110 |
Why?
|
| Internship and Residency | 1 | 2022 | 1001 | 0.110 |
Why?
|
| Prevalence | 4 | 2019 | 2326 | 0.110 |
Why?
|
| Adolescent | 4 | 2023 | 18480 | 0.110 |
Why?
|
| Internet | 1 | 2016 | 633 | 0.100 |
Why?
|
| Child, Preschool | 2 | 2022 | 9491 | 0.100 |
Why?
|
| Neovascularization, Physiologic | 2 | 2023 | 181 | 0.100 |
Why?
|
| Obesity, Abdominal | 1 | 2011 | 39 | 0.100 |
Why?
|
| Models, Biological | 1 | 2018 | 1715 | 0.100 |
Why?
|
| Electronic Health Records | 1 | 2018 | 829 | 0.100 |
Why?
|
| Protein Precursors | 2 | 2014 | 126 | 0.100 |
Why?
|
| Femoral Artery | 2 | 2022 | 175 | 0.090 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2016 | 811 | 0.090 |
Why?
|
| Receptors, Cell Surface | 1 | 2011 | 367 | 0.090 |
Why?
|
| Subclavian Steal Syndrome | 1 | 2009 | 2 | 0.090 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 524 | 0.090 |
Why?
|
| Bayes Theorem | 2 | 2023 | 344 | 0.090 |
Why?
|
| Troponin C | 1 | 2008 | 6 | 0.080 |
Why?
|
| Natriuretic Peptides | 1 | 2008 | 8 | 0.080 |
Why?
|
| Multivariate Analysis | 1 | 2012 | 1473 | 0.080 |
Why?
|
| Platelet Function Tests | 2 | 2018 | 25 | 0.080 |
Why?
|
| Endothelial Cells | 2 | 2023 | 732 | 0.080 |
Why?
|
| Death | 2 | 2020 | 105 | 0.070 |
Why?
|
| Body Weight | 2 | 2023 | 934 | 0.070 |
Why?
|
| Body Mass Index | 3 | 2023 | 2092 | 0.070 |
Why?
|
| Child | 2 | 2022 | 19129 | 0.070 |
Why?
|
| Heart Ventricles | 1 | 2010 | 727 | 0.070 |
Why?
|
| Emergency Medical Services | 1 | 2012 | 589 | 0.060 |
Why?
|
| Cost-Benefit Analysis | 2 | 2018 | 554 | 0.060 |
Why?
|
| Patient Discharge | 1 | 2010 | 796 | 0.060 |
Why?
|
| Recovery of Function | 2 | 2019 | 603 | 0.060 |
Why?
|
| Factor XI | 1 | 2023 | 6 | 0.060 |
Why?
|
| Case-Control Studies | 2 | 2022 | 3171 | 0.060 |
Why?
|
| Absorbable Implants | 1 | 2023 | 35 | 0.060 |
Why?
|
| Everolimus | 1 | 2023 | 64 | 0.060 |
Why?
|
| Inhibins | 1 | 2023 | 46 | 0.060 |
Why?
|
| Soluble Guanylyl Cyclase | 1 | 2022 | 15 | 0.060 |
Why?
|
| Multimorbidity | 1 | 2022 | 29 | 0.050 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2022 | 56 | 0.050 |
Why?
|
| Necrosis | 1 | 2023 | 230 | 0.050 |
Why?
|
| Animals | 5 | 2023 | 33381 | 0.050 |
Why?
|
| Mice | 3 | 2023 | 15520 | 0.050 |
Why?
|
| Sex Factors | 2 | 2021 | 1781 | 0.050 |
Why?
|
| Therapeutics | 1 | 2022 | 12 | 0.050 |
Why?
|
| Disease Progression | 2 | 2019 | 2490 | 0.050 |
Why?
|
| Tissue Scaffolds | 1 | 2023 | 184 | 0.050 |
Why?
|
| Evidence-Based Medicine | 2 | 2017 | 693 | 0.050 |
Why?
|
| Coated Materials, Biocompatible | 1 | 2021 | 58 | 0.050 |
Why?
|
| Sodium | 1 | 2022 | 200 | 0.050 |
Why?
|
| Observational Studies as Topic | 1 | 2021 | 89 | 0.050 |
Why?
|
| RNA, Small Interfering | 1 | 2023 | 564 | 0.050 |
Why?
|
| Genotyping Techniques | 1 | 2020 | 75 | 0.050 |
Why?
|
| Transforming Growth Factor beta | 1 | 2023 | 462 | 0.050 |
Why?
|
| Pregnancy | 1 | 2012 | 5690 | 0.050 |
Why?
|
| Drug Labeling | 1 | 2019 | 45 | 0.040 |
Why?
|
| Immunosuppressive Agents | 1 | 2023 | 681 | 0.040 |
Why?
|
| Machine Learning | 1 | 2022 | 331 | 0.040 |
Why?
|
| Aorta | 1 | 2021 | 367 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2022 | 527 | 0.040 |
Why?
|
| Research Support as Topic | 1 | 2020 | 114 | 0.040 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2018 | 57 | 0.040 |
Why?
|
| Osteoporotic Fractures | 1 | 2019 | 51 | 0.040 |
Why?
|
| Cardiotoxicity | 1 | 2018 | 29 | 0.040 |
Why?
|
| Republic of Korea | 1 | 2018 | 26 | 0.040 |
Why?
|
| Retinal Diseases | 1 | 2019 | 81 | 0.040 |
Why?
|
| Hip Fractures | 1 | 2019 | 79 | 0.040 |
Why?
|
| Diet, Reducing | 1 | 2019 | 81 | 0.040 |
Why?
|
| Sweden | 1 | 2018 | 63 | 0.040 |
Why?
|
| Spinal Fractures | 1 | 2019 | 77 | 0.040 |
Why?
|
| New Zealand | 1 | 2018 | 50 | 0.040 |
Why?
|
| NF-kappa B | 1 | 2022 | 670 | 0.040 |
Why?
|
| Advisory Committees | 1 | 2020 | 212 | 0.040 |
Why?
|
| Aortic Valve Insufficiency | 1 | 2018 | 42 | 0.040 |
Why?
|
| Diuresis | 1 | 2018 | 8 | 0.040 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2019 | 122 | 0.040 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2018 | 84 | 0.040 |
Why?
|
| Remission Induction | 1 | 2018 | 247 | 0.040 |
Why?
|
| Cerebral Infarction | 1 | 2018 | 45 | 0.040 |
Why?
|
| Pulmonary Embolism | 1 | 2020 | 183 | 0.040 |
Why?
|
| Insulin | 2 | 2018 | 2162 | 0.040 |
Why?
|
| Antiviral Agents | 1 | 2023 | 654 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2023 | 1635 | 0.040 |
Why?
|
| Logistic Models | 1 | 2022 | 1900 | 0.040 |
Why?
|
| Receptors, Purinergic P2Y12 | 1 | 2017 | 6 | 0.040 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2018 | 195 | 0.040 |
Why?
|
| Intensive Care Units | 1 | 2021 | 635 | 0.040 |
Why?
|
| Disease Susceptibility | 1 | 2019 | 331 | 0.040 |
Why?
|
| England | 1 | 2017 | 68 | 0.040 |
Why?
|
| Florida | 1 | 2017 | 73 | 0.040 |
Why?
|
| Risk Reduction Behavior | 1 | 2019 | 199 | 0.040 |
Why?
|
| Primary Prevention | 1 | 2018 | 185 | 0.040 |
Why?
|
| Glucose | 1 | 2022 | 953 | 0.040 |
Why?
|
| Up-Regulation | 1 | 2020 | 872 | 0.040 |
Why?
|
| Drug Monitoring | 1 | 2018 | 187 | 0.040 |
Why?
|
| Marfan Syndrome | 1 | 2016 | 42 | 0.040 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2018 | 301 | 0.040 |
Why?
|
| Health Promotion | 1 | 2022 | 691 | 0.030 |
Why?
|
| Microfilament Proteins | 1 | 2017 | 134 | 0.030 |
Why?
|
| Cell Adhesion Molecules | 1 | 2017 | 180 | 0.030 |
Why?
|
| Bone Density | 1 | 2019 | 449 | 0.030 |
Why?
|
| Curriculum | 1 | 2022 | 910 | 0.030 |
Why?
|
| Prediabetic State | 1 | 2018 | 234 | 0.030 |
Why?
|
| Long-Term Care | 1 | 2015 | 74 | 0.030 |
Why?
|
| Clinical Competence | 1 | 2022 | 951 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2016 | 341 | 0.030 |
Why?
|
| Mortality | 1 | 2017 | 299 | 0.030 |
Why?
|
| Vaccination | 1 | 2023 | 1222 | 0.030 |
Why?
|
| Phosphoproteins | 1 | 2017 | 308 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2017 | 827 | 0.030 |
Why?
|
| Publishing | 1 | 2016 | 131 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2022 | 1570 | 0.030 |
Why?
|
| Fractures, Bone | 1 | 2019 | 380 | 0.030 |
Why?
|
| Exercise Test | 1 | 2017 | 549 | 0.030 |
Why?
|
| Metformin | 1 | 2018 | 295 | 0.030 |
Why?
|
| United States Food and Drug Administration | 1 | 2015 | 175 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2017 | 995 | 0.030 |
Why?
|
| Sodium Channel Blockers | 1 | 2014 | 24 | 0.030 |
Why?
|
| Atrial Natriuretic Factor | 1 | 2014 | 59 | 0.030 |
Why?
|
| Fatty Acid Binding Protein 3 | 1 | 2013 | 4 | 0.030 |
Why?
|
| Limit of Detection | 1 | 2013 | 55 | 0.030 |
Why?
|
| Massachusetts | 1 | 2014 | 141 | 0.030 |
Why?
|
| Placenta Growth Factor | 1 | 2012 | 25 | 0.030 |
Why?
|
| Aortic Valve | 1 | 2016 | 401 | 0.030 |
Why?
|
| Norway | 1 | 2012 | 35 | 0.030 |
Why?
|
| Retreatment | 1 | 2012 | 71 | 0.030 |
Why?
|
| Creatinine | 1 | 2014 | 491 | 0.030 |
Why?
|
| Blood Pressure | 1 | 2019 | 1664 | 0.030 |
Why?
|
| Interleukin-1 Receptor-Like 1 Protein | 1 | 2011 | 24 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2022 | 4551 | 0.030 |
Why?
|
| Waist Circumference | 1 | 2011 | 130 | 0.020 |
Why?
|
| Anthropometry | 1 | 2011 | 194 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2022 | 5255 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2023 | 4709 | 0.020 |
Why?
|
| Creatine Kinase, MB Form | 1 | 2009 | 5 | 0.020 |
Why?
|
| Infant | 1 | 2022 | 8293 | 0.020 |
Why?
|
| Angiography | 1 | 2009 | 185 | 0.020 |
Why?
|
| Atherectomy | 1 | 2008 | 33 | 0.020 |
Why?
|
| Echocardiography | 1 | 2010 | 556 | 0.020 |
Why?
|
| Hypertension, Pulmonary | 1 | 2018 | 1794 | 0.020 |
Why?
|
| Hemodynamics | 1 | 2011 | 1003 | 0.020 |
Why?
|
| Preoperative Care | 1 | 2008 | 332 | 0.020 |
Why?
|
| Research Design | 1 | 2009 | 969 | 0.010 |
Why?
|